Cat. No. 4962
Chemical Name: (3R,5S)-rel-5-[6-(2,4-Dichloropheny
Biological ActivityATP citrate lyase (ACLY) inhibitor. Prodrug of SB 201076. Inhibits cholesterol and fatty acid synthesis in a dose-dependent manner in HepG2 cells. Orally active in vivo.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Gribble et al (1998) ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R*,5S*)-ω-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo. J.Med.Chem. 41 3582. PMID: 9733484.
Pearce et al (1998) The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem.J. 334 113. PMID: 9693110.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SB 204990 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SB 204990, supplier, SB204990, ATP-citrate, lyases, ACL, inhibitors, inhibits, prodrug, SB-201076, cholesterol, fatty, acid, metabolic, lipids, synthases, transferases, ACLY, Tocris Bioscience, ATP Citrate Lyase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent cholesteryl ester transfer protein (CETP) inhibitorPerhexiline maleate
Carnitine palmitoyltransferase 1 and 2 (CPT1/2) inhibitorMS 023 dihydrochloride
Potent and selective type I PRMT inhibitorP-3FAX-Neu5Ac
Sialic acid analog; sialyltransferase inhibitorTolcapone
COMT inhibitor; also inhibits transthyretin aggregationJNJ DGAT2-A
DGAT2 inhibitorLLY 507
Potent SMYD2 inhibitor
December 3 - 7, 2016
San Francisco, CA,